Breeze Airways Celebrates Four Years of Flying with Network-Wide Promotion
'Breeze is proving that affordable air travel can still be a nice experience, with free family seating, fast WiFi, an upgraded seat, and no change or cancel fees.'— David Neeleman, Breeze Airways' founder and CEO
SALT LAKE CITY, UT, UNITED STATES, May 27, 2025 / EINPresswire.com / -- Breeze Airways, the premium leisure carrier connecting underserved cities across the U.S., today celebrates its fourth anniversary of delivering convenient, affordable air service to millions of Guests across its growing nationwide network.
Since completing its first flight on May 27, 2021, Breeze has become one of the fastest growing airlines in the world, now operating more than 300 direct routes to 72 cities in 32 states. Its 'Seriously Nice' business model combines affordability and flexibility with the premium products and services travelers desire on its brand new fleet of A220-300 aircraft.
'In four short years, Breeze has defied gravity by bringing our unique combination of elevated, yet affordable service to hundreds of underserved city pairs across the U.S.,' said David Neeleman, Breeze Airways founder and CEO. 'What's more, we have done so while also creating an award-winning experience and that has won over the hearts and minds of millions of travelers coast-to-coast by getting them there twice as fast for half the cost.'
Saving Time
Over the past two decades, underserved and secondary markets have continued to see reductions in air service as mainline carriers maintain the dominant share of the domestic air travel market. To combat this, Breeze established a flexible network to bring affordable air service back to these communities with convenient, direct flights to desirable destinations nationwide.
As the only nonstop option on 87% of its more than 250 nonstop routes, Breeze makes air travel more convenient by reducing unnecessary travel time spent driving to larger airports, waiting in long security lines, and making multiple connections before reaching your destination.
Additionally, the airline's seamless technology platform empowers Guests to quickly and easily book and manage their flight details and preferences. Through AI-powered tools and chat-based support, nearly 40% of conversations are resolved before reaching a Team Member, resulting in Guest satisfaction scores that continue to increase year over year. Recently, the airline expanded its support features to include an in-app chat option, making Breeze's app one of the most comprehensive applications in the industry.
Saving Money
With fares on average 44% lower than other carriers serving the same city pairs, Breeze is also redefining travelers' expectations for low-cost carriers.
'Breeze is proving that affordable air travel can still be a nice experience, with bundles and a-la-carte options that fit everyone's travel needs,' Neeleman said. 'Whether you want free family seating, fast WiFi, an upgraded seat, or no change or cancel fees, Breeze is making it nice to fly affordably.'
In celebration of its fourth anniversary, Breeze introduced a network-wide promotion in which Guests can save 44% off the base fare of their next flight by using code 'BIRTHDAY' at booking. The promotion is on sale through May 30, 2025 (11:59pm ET) for travel between June 11, 2025 and January 6, 2026.
'We're grateful for our incredible Team Members, business and community partners, and Guests who have supported us the last four years,' Neeleman continued. 'Our ongoing growth is thanks to them, and we look forward to continuing that momentum in the coming months and years.'
To learn more about Breeze or to book a flight, visit flybreeze.com or download the Breeze Airways app.
###
*44% base fare discount applies only to new reservations for round-trip flights with promo code BIRTHDAY. Supply is limited, and no advance purchase requirement applies. Promotion must be purchased at flybreeze.com or on the Breeze app from May 27, 2025, through May 30, 2025 (11:59 pm PT), for travel from June 11, 2025, through January 6, 2026. Promotion excludes travel from July 5, 2025, through July 7, 2025; on September 1, 2025; from October 10, 2025, through October 13, 2025; from November 20, 2025, through November 26, 2025; from November 28, 2025, through November 30, 2025; from December 19, 2025, through December 23, 2025; and from December 26, 2025, through January 4, 2026. Travel must be flown on qualifying travel dates for discount to be applied in full. The discount will apply only to flights on qualifying travel dates. All fare rules will apply. Certain flights and/or days of travel may be unavailable. Fare prices, fare classes, rules, routes, and schedules are subject to change or exemption without notice. Promotion cannot be combined with any other offer. Any changes or modifications to qualifying promotional reservations will be subject to fare repricing. A difference in airfare at the current fare price may apply. Offer not valid on group bookings. Other restrictions and blackout dates may apply.
About Breeze Airways
Breeze Airways operates more than 300 year-round and seasonal routes to 72 cities in 32 states. Founded by aviation entrepreneur David Neeleman, Breeze took flight in May 2021 bringing premium, affordable, and nonstop air service to secondary markets on its flagship fleet of Airbus A220-300 aircraft. Breeze has been named a top 5 'Best Domestic Airline' by Travel + Leisure for three consecutive years and was named one of Fast Company's Most Innovative Companies in 2025. Breeze was the first U.S. domestic airline to be certified by Autism Double Checked and is the official airline of Make-a-Wish Utah. With seamless booking, friendly policies, and customized booking options, Breeze makes it easy to buy and Seriously Nice™ to fly.
McKinnley Matson
Breeze Airways
+1 801-436-3984
email us here
Visit us on social media:
YouTube
TikTok
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox Sports
a day ago
- Fox Sports
Fox Corporation Announces One-Third Interest Acquisition Of Penske Entertainment
Fox Corporation and Penske Entertainment made a landmark announcement on Thursday morning, as FOX has acquired a one-third interest in Penske Entertainment, related to INDYCAR and Indianapolis Motor Speedway. The move comes with the intention of having high-profile racing and entertainment events, prioritizing quality digital content and having more promotion of the NTT INDYCAR Series and its drivers. "This partnership is built on long-standing trust and a shared vision for the future," team owner Roger Penske said in a statement. "FOX sees the incredible potential across our sport and wants to play an active role in building our growth trajectory. Lachlan Murdoch and his team, starting with Eric Shanks, are committed to our success and will bring incredible energy and innovation to INDYCAR." Penske Entertainment, a subsidiary of Penske Corporation, is a primary provider of sports and entertainment. It operates in a range of fields, including professional motorsports, truck leasing and transportation logistics. Penske Entertainment has more than 3,300 locations. "We're thrilled to join the INDYCAR ownership group at such a pivotal time for the sport," FOX Sports CEO & Executive Producer Eric Shanks said in a statement. "INDYCAR represents everything we value in live sports — passionate fans, iconic venues, elite competition and year-round storytelling potential. This investment underscores our commitment to motorsports and our belief in INDYCAR's continued growth on and off the track. We're excited to help elevate the sport to new heights across all platforms." This news comes against the backdrop of FOX Sports agreeing to a multi-year extension to maintain exclusive INDYCAR media rights. The current 2025 INDYCAR season is the first year of the sport's respective races airing on FOX networks. At present, the sport is averaging a 31% increase in viewership year-over-year. This year's running of the Indianapolis 500, which was won by Alex Palou, averaged 7.01 million viewers, which was a 41% increase from 2024 and a 17-year-high. The race also had more than 300,000 fans present. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account, and follow leagues, teams and players to receive a personalized newsletter daily! FOLLOW Follow your favorites to personalize your FOX Sports experience NTT INDYCAR SERIES Team Penske Get more from the NTT INDYCAR SERIES Follow your favorites to get information about games, news and more in this topic
Travel Weekly
a day ago
- Travel Weekly
Alaska Airlines is launching Burbank routes to fill Avelo void
Alaska is the latest airline gunning to take up the void that Avelo Airlines will leave at Hollywood Burbank Airport. Alaska said Thursday that it will launch year-round, daily routes connecting Burbank with Eugene, Ore.; Redmond/Bend, Ore.; and Pasco, Wash. The flights commence Oct. 26 and will be operated with regional Embraer E175 planes. All three routes are currently served by discounter Avelo, which announced this month that it will pull out of Burbank on Dec. 2. Discount carrier Breeze plans to be fighting against Alaska for Avelo's market share, having announced its own service plans from Burbank to Eugene, Pasco and Bend, as well to Eureka, Calif., and Provo, Utah. Breeze is entering Burbank, but Alaska's there But Alaska will have the jump on Breeze. The Seattle-based airline already flies to five destinations from Burbank, while Breeze will be a new entrant to the airport. And Breeze's Burbank flights won't begin until March, several months after the new Alaska operations. The Burbank announcements are among seven newly planned routes Alaska unveiled Thursday connecting California to the northwest. The airline will also begin daily Ontario, Calif.-Boise, Idaho, service and daily Orange County-Spokane, Wash., service on Jan. 7. In addition, Alaska will fly winter seasonally between Santa Rosa, Calif., and Palm Springs five-times weekly beginning Oct. 26 and winter seasonally thrice-weekly between San Diego and the skiing destination of Sun Valley, Idaho, beginning Dec. 18. Alaska is scheduled to be the lone carrier flying between Ontario and Boise, Cirium flight schedule data shows. Alaska will also be the only carrier connecting San Diego with Sun Valley, and it will be alone on Santa Rosa-Palm Springs, replacing Avelo service that was discontinued in June. On Orange County-Spokane, Allegiant currently offers summer seasonal service.
Business Wire
2 days ago
- Business Wire
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the successful completion of targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan. The company enrolled 10 patients ahead of schedule across five clinical sites in Japan, including the National Cancer Center Japan. The HARMONIC™ trial is evaluating LP-300 in combination with carboplatin and pemetrexed in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The successful Japanese enrollment validates Lantern's strategic decision to expand the trial internationally to regions with significantly higher rates of never-smoker NSCLC patients such as Japan and Taiwan. "Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence," said Panna Sharma, President and CEO of Lantern Pharma. "This achievement builds momentum as we continue enrollment in Taiwan and the United States, bringing us closer to generating the clinical data that could establish LP-300 as a treatment option for this underserved patient population with significant unmet medical need." The completion of Japanese enrollment represents an important milestone in the global HARMONIC™ trial, which is designed to enroll approximately 90 patients across multiple regions. Japan's notably higher rate of never-smoker NSCLC patients (33-40% of new cases) compared to Western populations (typically 15%) makes it a strategically important region for the trial. Similarly, Taiwan, where more than 50% of lung cancer cases occur in never-smokers, represents another key enrollment region. The HARMONIC™ trial previously demonstrated encouraging results in its initial safety lead-in cohort, showing an 86% clinical benefit rate and 43% objective response rate among the first seven patients enrolled in the United States. Notably, recent data revealed that one patient has achieved a durable complete response in target cancer lesions with survival continuing for nearly two years, demonstrating the potential for LP-300 to deliver meaningful long-term outcomes for never-smoker NSCLC patients. Never-smoker NSCLC is increasingly recognized as a distinct disease entity with unique clinical and genomic characteristics 1, representing a global market opportunity estimated at over $4 billion annually. Currently, there are no therapies specifically approved for never-smoker NSCLC patients, highlighting the significant unmet medical need this population faces. Lantern is actively exploring collaboration and partnering opportunities to maximize LP-300's commercial potential in multiple geographies. Lantern is scheduled to provide further clinical and outcome data from the HARMONIC™ trial later this quarter, with updates covering both Asian and U.S. patient cohorts. About LP-300 LP-300 is a disulfide small molecule and investigational drug candidate with a multimodal mechanism of action directed toward tyrosine kinase receptors and cell redox enzymes. It modulates cellular redox in key signaling pathways in NSCLC and directly engages with TKI receptors via cysteine modification. LP-300 has been evaluated in multiple Phase 1, 2, and 3 clinical trials in over 1,000 subjects, with retrospective analysis showing significant survival benefit in never-smoker lung adenocarcinoma patients. About the HARMONIC™ Trial The HARMONIC™ trial is a multicenter, open-label, randomized Phase 2 trial designed to evaluate the efficacy and safety of LP-300 in combination with standard-of-care chemotherapy (pemetrexed/carboplatin) versus chemotherapy alone in never-smoker NSCLC patients who have relapsed following TKI treatment. The trial is expected to enroll approximately 90 patients across sites in the United States, Japan, and Taiwan. The primary endpoints are progression-free survival (PFS) and overall survival (OS). For more information about the trial, visit or (NCT05456256). About Lantern Pharma: Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world. Please find more information at: Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024, under the investor SEC filings tab of our website at ( or on the SEC's website at ( Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. 1 Saito M, Shiraishi K, Matsumoto K, Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H, Watanabe SI, Kamma H, Asamura H, Yamamoto S, Tan EM, Wang JY, Harris CC, Yokota J, Kohno T, Goto A. Lung cancer in patients who have never smoked — an emerging disease. PMC. 2024.
